More than half of the drugs in the EU market are used for cancer treatments, according to the European Medicines Agency.
It’s the biggest market for the drugs and, while the pharmaceutical companies in the European Union do a good job, they’re not the main players in the industry, according the European Commission.
In an interview with the BBC, Dr Daniel Drezner, the commissioner of competition in the commission, said it’s “very important to have a clear understanding of what’s happening in the pharmaceutical sector”.
In a bid to address the issue, the European commission has put together a list of 15 drugs that it says are of “serious” concern to the health of the public.
What the list says The medicines in the list are: The anti-coagulant drug Nolvadex is one of the most commonly prescribed medicines in Europe, and one of Europe’s top cancer treatments.
Nolvaderx is used to treat cancer, glioma and other types of cancer.
It has been shown to be safe and effective, and is used in more than 40 countries.
Another drugs in Dr Dreznner’s list is dutasteride, an anti-inflammatory drug.
The US drug company AstraZeneca also uses dutasterein to treat osteoarthritis.
But the EU says AstraZymed also uses Nolvik.
“We believe this list is very relevant to the debate on the future of the pharmaceutical market and the future prospects for the future in Europe,” said Dr Drexler.
“We think it is important to be aware of what the drugs are in the market.”
Other medicines on the list that are not in the public market include: Elevate, a drug for the treatment of heart failure, which is used widely in the US, Canada, France and many other countries.